Development Intelligence Platform · Biopharma & CDMOs
See risk before it becomes a delay
BioXion is an AI-powered development intelligence platform for biopharmaceutical companies and CDMOs. It connects Program Development, analytical, quality, regulatory, and supply chain data — and gives leadership the visibility to act before programs fall behind.
From preclinical to commercial — one intelligence platform for biopharma and CDMOs.
The problem
Your program is running blind. Your tools aren’t built to fix that.
Most development delays don't come from science — they come from broken coordination between partners. Program Development data lives in one system, CDMO performance in another, quality events in a third. No team sees the complete picture until the delay is already a fact.
BioXion is built specifically for this problem. It aggregates signals across every development function — Program Development, CDMO, analytical, quality, regulatory, supply chain — and surfaces cross-functional risk before it cascades into a timeline or regulatory consequence. The four failure modes below define what disconnected program intelligence looks like in practice.
01
No one sees the full picture
Program Development, quality, CDMO, and regulatory data live in separate systems. Cross-functional risk is invisible — until it’s already a delay.
02
Decisions are made without context
By the time a signal reaches leadership, it’s already a problem. The window to act has closed.
03
Regulatory gaps appear at inspection
FDA, EMA, and ICH guidance is tracked manually — with no link to active programs. Deficiencies are found at review, not before.
04
You’re managing the past
Every current tool tells you what happened. None of them tell you what’s about to go wrong — and what it will cost your program.
The platform
One intelligence platform. Every development function.
BioXion doesn’t replace your systems — it gives you a unified view across them. It sits above your QMS, LIMS, and ELN as a program-level intelligence platform, reading data across every function and surfacing what no individual tool can see.
✦AI is not a module or a chatbot. It is the engine beneath the platform — continuously scoring readiness, detecting cross-functional risk, and mapping your program against current regulatory expectations. Every signal is explainable. Every output is traceable.
Under development
⬡
Under development
Program Development Navigator
Know where your program stands — at every phase, across every workstream
▾
An AI-generated Program Development plan from preclinical to commercial — covering Drug Substance, Drug Product, Analytical, and Regulatory workstreams across 9 modalities. Every step linked to regulatory context and readiness status.
✦
Under development
AI Intelligence Dashboard
Readiness scored. Risks ranked. No dashboard required.
▾
Program readiness calculated continuously from live data across all modules. Risks ranked by severity, phase, and regulatory impact — each explained in plain language with the guidance that triggered it.
Coming soon
◈
Coming soon
Partner Programs
Track every partner commitment — before it becomes a program risk
▾
Sponsor-side CDMO oversight and CDMO-side client program management — on the same data model. Tracks tech-transfer milestones, manufacturing deliverables, audit findings, and partner risk across every manufacturing site. Linked to Program Development steps and quality events so gaps don't stay invisible until a batch fails.
◎
Coming soon
Analytical Intelligence
Catch method failures before they delay your submission
▾
Full method lifecycle management — development, qualification, validation, and transfer — with AI monitoring and early alerts before issues enter the formal review cycle.
◉
Coming soon
Quality Intelligence
Connect quality events to the programs they affect
▾
Deviations, CAPAs, change controls, and audit readiness — each linked to the Program Development step and CDMO activity it affects. Quality signals propagate automatically across your program.
On the roadmap
⬖
On the roadmap
Regulatory Intelligence
Know your submission gaps before the agency finds them
▾
Submission portfolio management across FDA, EMA, ICH, and Swissmedic — with AI readiness scoring and real-time monitoring of new guidance against your active programs.
⬡
On the roadmap
Supply Chain Intelligence
Surface supply risk before it disrupts your clinical timeline
▾
Real-time visibility into material availability, CDMO capacity, and cold chain integrity — linked to active manufacturing campaigns and clinical milestones.
✦
Also from Helvetia Tech Solutions
BioXion covers the program. FormulytiX covers the molecule.
FormulytiX is the companion platform for drug product formulation teams — bringing AI-driven excipient intelligence, stability prediction, and regulatory formulation guidance for both large and small molecules. Where BioXion manages your development program, FormulytiX optimizes what goes inside the vial.
The Program Intelligence Dashboard gives leadership a complete, live view of program health — readiness score, open risk signals, active milestones, and regulatory gaps — without opening a single system or waiting for a status update.
Program Intelligence Dashboard
Readiness · Open risks · Active milestones · Regulatory signals
✦ AI-powered
Built for decision makers
For the leaders who can’t afford to be the last to know
◎
Portfolio visibility
Every program. Every function. Every site. One view — updated in real time, without chasing status reports.
◈
Readiness scoring
A single number that reflects where your program actually stands — calculated from live data, not PowerPoint slides.
✦
Strategic signals
Risk surfaced before it becomes delay. Regulatory gaps flagged before inspection. Decisions made on facts, not instinct.
⬡
BioXion doesn’t replace your systems — it gives you a unified view across them.
Users reference their program documents directly within BioXion. The platform reads, interprets, and connects that information — giving leadership a complete intelligence picture without touching your existing infrastructure.
Use cases
Where BioXion delivers impact
Program Development Planning
BioXion provides development teams with an AI-generated Program Development plan that adapts to therapeutic modality, development phase, and regulatory target. Instead of building roadmaps manually from guidance documents, teams get a structured, phase-appropriate plan with regulatory context embedded at every step — eliminating the risk of missing critical Program Development milestones before IND or BLA submission.
Partner Programs
Managing contract manufacturing partnerships is one of the highest-risk activities in drug development — for sponsors and CDMOs alike. BioXion consolidates partner oversight into a single intelligence platform, tracking tech-transfer milestones, manufacturing deliverables, audit findings, and partner risk in real time. Program coordination becomes proactive, not reactive.
GMP Readiness & Risk Monitoring
GMP readiness failures are rarely sudden — they are the result of signals that were present but not connected. BioXion continuously monitors quality events, deviation patterns, and CDMO performance data to surface GMP readiness risks before they escalate. This AI platform for drug development gives quality and operations teams the early warning they need to act.
Cross-Functional Intelligence
In complex development programs, a regulatory gap can delay a manufacturing campaign; a partner issue can trigger a quality event; a Program Development deviation can affect submission readiness. BioXion maps these cross-functional dependencies automatically — giving leadership a connected view of program risk that no individual system or team can produce alone.
Knowledge base
Explore BioXion Intelligence Modules
Each module in the BioXion platform addresses a distinct Program Development function. Below is the knowledge base — built from 15+ years of biopharma and CDMO industry experience and the same domain logic that powers the platform.
No — intentionally. BioXion is a non-GxP program intelligence platform. It operates above your validated infrastructure, structuring and linking key program information without touching your QMS, LIMS, or ELN. It is a non-GxP decision-support layer, not the system of record for regulated GMP data; customer validation expectations depend on intended use.
No. BioXion doesn’t compete with your QMS, LIMS, or ELN — it gives you a unified view across them. Think of it as the intelligence platform that sits above your existing stack and surfaces what those systems can’t show you individually.
BioXion can operate without mandatory IT integration during early deployment, and is designed with an open integration approach so customers can later connect relevant eQMS, LIMS, ELN or other systems where appropriate. BioXion works independently — your team inputs and structures data directly within the platform.
Your team enters it directly. BioXion is built around structured manual inputs — program data, milestones, decisions, and references to existing documents. BioXion can operate without mandatory IT integration during early deployment.
Early access partners are onboarded in a structured process designed to deliver first program visibility within weeks, not months. We work directly with your team to configure the platform around your program structure and existing data.
All data is hosted in Switzerland (Infomaniak/Jelastic). AI processing runs on sovereign, Swiss-hosted large language models (Azure Switzerland North). BioXion is designed for Swiss hosting with tenant isolation, and enterprise customers can define stricter AI-processing requirements where needed. Entity masking is applied before any data reaches the AI layer.
9 modalities: Small Molecule, mAb, ADC, mRNA, Recombinant Protein, Viral Vector Vaccine, Cell Therapy, Gene Therapy, and Oligonucleotide — plus Custom Modality. Each has modality-specific regulatory logic and Program Development structure built in.
No. BioXion is designed to support programs from Preclinical through Commercial — and to remain the intelligence backbone through Phase III, post-approval changes, and product lifecycle management.
BioXion is built for Program Development Directors, Heads of Development, Regulatory Affairs leads, and program managers at biopharmaceutical companies and CDMOs — typically those managing complex development programs across multiple partners and regulatory markets where cross-functional visibility is critical.
Early access is by application. We're onboarding a selected group of partners who will help shape the product. Schedule a call using the form below, or reach out directly at [email protected] — and we'll follow up within 48 hours.
The Team
The team behind BioXion
A founding team combining 15+ years of biopharma development experience, deep scientific expertise, and operational discipline — building the development intelligence platform we wished existed.
Sinisa Popov
Founder & CEO
15+ yrs biopharma industry experience
External Quality at MSD (Merck & Co.)
PhD Biologics & Vaccines Formulations (active)
MSc Chemistry · Six Sigma Black Belt
Slim Chaker
COO · Project Management & Operations
MSc Mechanical Engineering
R&D, production & process engineering
CAD & FEM engineering (Creo, Solidworks, Ansys)
Early Access
Your next program delay is already visible — if you know where to look.
BioXion gives your leadership team the visibility to act before programs fall behind. We’re onboarding a selected group of early access partners. Let’s see what your program data reveals.
No commitment required
30-minute intro call
Direct access to the founding team
Schedule a callvia Microsoft Bookings
Pick a slot that works for you
30-minute intro call with the founding team. No commitment — bring your questions, share your context, and we'll show you how BioXion fits your program reality.
